This research study is evaluating an investigational medication for IgA nephropathy (IgAN) in adults. You may be able to take part in this study if you:
Are at least 18 years of age
Have been diagnosed with IgAN
Have been on stable therapy for IgAN for at least 12 weeks
Have no other disease that affects your kidneys
The study will involve up to 40 visits over the course of about two years and is divided into two year-long periods. Those who qualify will receive either the investigational medication or a placebo (a substance that looks like the investigational medication but contains no active ingredients), in addition to standard-of-care therapy.
Each year-long period includes 22 weeks of subcutaneous (under the skin) injections (weekly for 9 doses, then every other week for 7 doses), followed by a 30-week dosing-free phase. Those who complete the study may be eligible for a continuation study.
Participation can last about two years, which includes up to 40 visits to the study centre.
The investigational medication is a compound that aims to slow down the progression of IgAN by reducing how much of the defective IgA protein is produced in the body. It will be given as a subcutaneous (under the skin) injection.
Do not discontinue any medication unless you are advised to do so by the study staff or your primary care provider.
Travel-related support as well as compensation for time spent during site visits for this study may be available depending on country and site regulatory approvals. The investigational medication, placebo and all study-related tests will be provided to participants during their study participation.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside the guidelines for this study. This does not mean you won’t be able to take part in other research studies.
This research study is evaluating an investigational medication for IgA nephropathy (IgAN) in adults. You may be able to take part in this study if you:
Are at least 18 years of age
Have been diagnosed with IgAN
Have been on stable therapy for IgAN for at least 12 weeks
Have no other disease that affects your kidneys
The study will involve up to 40 visits over the course of about two years and is divided into two year-long periods. Those who qualify will receive either the investigational medication or a placebo (a substance that looks like the investigational medication but contains no active ingredients), in addition to standard-of-care therapy.
Each year-long period includes 22 weeks of subcutaneous (under the skin) injections (weekly for 9 doses, then every other week for 7 doses), followed by a 30-week dosing-free phase. Those who complete the study may be eligible for a continuation study.
Participation can last about two years, which includes up to 40 visits to the study centre.
The investigational medication is a compound that aims to slow down the progression of IgAN by reducing how much of the defective IgA protein is produced in the body. It will be given as a subcutaneous (under the skin) injection.
Do not discontinue any medication unless you are advised to do so by the study staff or your primary care provider.
Travel-related support as well as compensation for time spent during site visits for this study may be available depending on country and site regulatory approvals. The investigational medication, placebo and all study-related tests will be provided to participants during their study participation.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside the guidelines for this study. This does not mean you won’t be able to take part in other research studies.
You are now leaving www.amigastudy.com and being redirected to a website that is not operated by Clinical Trial Media Inc.
